{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:56:31Z","timestamp":1777694191160,"version":"3.51.4"},"reference-count":114,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurosurgery Clinics of North America"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.nec.2012.06.012","type":"journal-article","created":{"date-parts":[[2012,10,2]],"date-time":"2012-10-02T20:40:53Z","timestamp":1349210453000},"page":"653-668","source":"Crossref","is-referenced-by-count":27,"title":["Medical Management of Persistent and Recurrent Cushing Disease"],"prefix":"10.1016","volume":"23","author":[{"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.nec.2012.06.012_bib1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1210\/jc.86.1.117","article-title":"Incidence and late prognosis of Cushing\u2019s syndrome: a population-based study","volume":"86","author":"Lindholm","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.nec.2012.06.012_bib2","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1365-2265.2010.03961.x","article-title":"The incidence and prevalence of Cushing's disease may be higher than previously thought: results from a retrospective study in Iceland 1955 through 2009","volume":"74","author":"Arnardottir","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1365-2265.2011.04124.x","article-title":"Mortality and morbidity in Cushing's syndrome in New Zealand","volume":"75","author":"Bolland","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"10.1016\/j.nec.2012.06.012_bib4","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2006-1668","article-title":"High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege","volume":"91","author":"Daly","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.nec.2012.06.012_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.nec.2012.06.012_bib6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-009-9888-2","article-title":"An approach to the management of patients with residual Cushing's disease","volume":"94","author":"Blevins","year":"2009","journal-title":"J\u00a0Neurooncol"},{"issue":"12","key":"10.1016\/j.nec.2012.06.012_bib7","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1210\/jc.2003-030254","article-title":"Occult Cushing's syndrome in type-2 diabetes","volume":"88","author":"Catargi","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.nec.2012.06.012_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/0003-4819-147-8-200710160-00006","article-title":"Subclinical hypercortisolism among outpatients referred for osteoporosis","volume":"147","author":"Chiodini","year":"2007","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.nec.2012.06.012_bib9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1365-2265.1996.737558.x","article-title":"Pre-clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients","volume":"44","author":"Leibowitz","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"10.1016\/j.nec.2012.06.012_bib10","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1210\/jc.2003-030871","article-title":"Diagnosis and complications of Cushing's syndrome: a consensus statement","volume":"88","author":"Arnaldi","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.nec.2012.06.012_bib11","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1210\/jc.2009-0766","article-title":"Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome","volume":"94","author":"Barahona","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.nec.2012.06.012_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000318566","article-title":"Cardiovascular disease in Cushing's syndrome: heart versus vasculature","volume":"92","author":"De Leo","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.nec.2012.06.012_bib13","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2265.2011.04206.x","article-title":"Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure","volume":"76","author":"Toja","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1210\/jc.2009-1672","article-title":"Delayed remission after transsphenoidal surgery in patients with Cushing's disease","volume":"95","author":"Valassi","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.nec.2012.06.012_bib15","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1590\/S0004-27302007000800025","article-title":"Cushing's syndrome: aftermath of the cure","volume":"51","author":"Pivonello","year":"2007","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.nec.2012.06.012_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000330416","article-title":"Adipokines and cardiovascular risk in Cushing's syndrome","volume":"95","author":"Valassi","year":"2011","journal-title":"Neuroendocrinology"},{"issue":"3","key":"10.1016\/j.nec.2012.06.012_bib17","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1210\/jc.2010-1942","article-title":"Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature","volume":"96","author":"Clayton","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.nec.2012.06.012_bib18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11102-011-0308-1","article-title":"Excess mortality for patients with residual disease following resection of pituitary adenomas","volume":"14","author":"Sughrue","year":"2011","journal-title":"Pituitary"},{"issue":"7","key":"10.1016\/j.nec.2012.06.012_bib19","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement","volume":"93","author":"Biller","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.nec.2012.06.012_bib20","first-page":"553","article-title":"Controversies in the management of Cushing's disease","volume":"33","author":"Chandler","year":"1986","journal-title":"Clin Neurosurg"},{"issue":"5","key":"10.1016\/j.nec.2012.06.012_bib21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2265.2001.01261.x","article-title":"Transsphenoidal pituitary surgery in Cushing's disease: can we predict outcome?","volume":"54","author":"Chee","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"10.1016\/j.nec.2012.06.012_bib22","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/ncpendmet0947","article-title":"Management of recurrent and refractory Cushing disease","volume":"4","author":"Aghi","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.nec.2012.06.012_bib23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrendo.2011.12","article-title":"Management of Cushing disease","volume":"7","author":"Tritos","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"10.1016\/j.nec.2012.06.012_bib24","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1590\/S0004-27302007000800023","article-title":"Criteria of cure and remission in Cushing's disease: an update","volume":"51","author":"Czepielewski","year":"2007","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/MED.0b013e328248b498","article-title":"Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful","volume":"14","author":"Fleseriu","year":"2007","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ecl.2005.01.007","article-title":"Pituitary surgery and postoperative management in Cushing's disease","volume":"34","author":"Utz","year":"2005","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"10.1016\/j.nec.2012.06.012_bib27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2005.02380.x","article-title":"Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance","volume":"63","author":"Atkinson","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1210\/jc.2007-2013","article-title":"Late recurrences of Cushing's disease after initial successful transsphenoidal surgery","volume":"93","author":"Patil","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib29","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3171\/jns.2004.100.4.0634","article-title":"Transsphenoidal surgery in Cushing disease: 10 years of experience in 34 consecutive cases","volume":"100","author":"Hoybye","year":"2004","journal-title":"J\u00a0Neurosurg"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1210\/edrv-14-4-443","article-title":"The medical treatment of Cushing's syndrome","volume":"14","author":"Miller","year":"1993","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.nec.2012.06.012_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ecl.2007.10.010","article-title":"Cushing's syndrome","volume":"37","author":"Pivonello","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.nec.2012.06.012_bib32","doi-asserted-by":"crossref","unstructured":"Baudry C, Coste J, Khalil RB, et\u00a0al. Results of 1, Ortho-1, para\u2032-Dichloro-Diphenyl-Dichloroethane (O, p\u2032DDD) treatment in 76 patients with Cushing disease. Presented at ENDO 2011. Boston, June 4, 2011.","DOI":"10.1210\/endo-meetings.2011.PART1.OR10.OR09-4"},{"issue":"1","key":"10.1016\/j.nec.2012.06.012_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/EJE-07-0514","article-title":"Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease","volume":"158","author":"Castinetti","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.nec.2012.06.012_bib34","doi-asserted-by":"crossref","unstructured":"Colao A, Petersenn S, Newell-Price J, et\u00a0al. Pasireotide (SOM230) demonstrates efficacy in patients with Cushing disease: results from a large, randomized-dose, double-blind, phase III study. Presented at ENDO 2011. Boston, June 4, 2011.","DOI":"10.1210\/endo-meetings.2011.PART1.OR10.OR09-6"},{"issue":"5","key":"10.1016\/j.nec.2012.06.012_bib35","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EJE-10-0382","article-title":"Cabergoline monotherapy in the long-term treatment of Cushing's disease","volume":"163","author":"Godbout","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.nec.2012.06.012_bib36","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A\u00a012-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib37","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1210\/jc.84.2.440","article-title":"Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study group of the Italian Society of Endocrinology on the pathophysiology of the hypothalamic-pituitary-adrenal axis","volume":"84","author":"Invitti","year":"1999","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.nec.2012.06.012_bib38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000091580","article-title":"Treatment of Cushing's disease: a retrospective clinical study of the latest 100 cases","volume":"34","author":"Hofmann","year":"2006","journal-title":"Front Horm Res"},{"issue":"1","key":"10.1016\/j.nec.2012.06.012_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3171\/jns.1994.80.1.0037","article-title":"Early repeat surgery for persistent Cushing's disease","volume":"80","author":"Ram","year":"1994","journal-title":"J\u00a0Neurosurg"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib40","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3171\/jns.1989.71.4.0520","article-title":"Repeat transsphenoidal surgery for Cushing's disease","volume":"71","author":"Friedman","year":"1989","journal-title":"J\u00a0Neurosurg"},{"issue":"Suppl 1","key":"10.1016\/j.nec.2012.06.012_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000314299","article-title":"Pituitary radiotherapy for Cushing's disease","volume":"92","author":"Losa","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib42","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ecl.2005.01.006","article-title":"Laparoscopic adrenalectomy for patients who have Cushing's syndrome","volume":"34","author":"Young","year":"2005","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"10.1016\/j.nec.2012.06.012_bib43","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1210\/jc.2006-1328","article-title":"Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome","volume":"92","author":"Assie","year":"2007","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1022308429992","article-title":"Medical therapy of Cushing's disease","volume":"5","author":"Nieman","year":"2002","journal-title":"Pituitary"},{"issue":"7","key":"10.1016\/j.nec.2012.06.012_bib45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/BF03347989","article-title":"Failure of long-term therapy with sodium valproate in Cushing's disease","volume":"20","author":"Colao","year":"1997","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.nec.2012.06.012_bib46","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","article-title":"Dopamine receptor expression and function in corticotroph pituitary tumors","volume":"89","author":"Pivonello","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib47","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","article-title":"The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5","volume":"152","author":"Hofland","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.nec.2012.06.012_bib48","first-page":"R233","article-title":"The role of somatostatin and dopamine D2 receptors in endocrine tumors","volume":"18","author":"Gatto","year":"2011","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.nec.2012.06.012_bib49","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1210\/jcem-56-6-1094","article-title":"Effects of cyproheptadine, reserpine, and synthetic corticotropin-releasing factor on pituitary glands from patients with Cushing's disease","volume":"56","author":"Suda","year":"1983","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/BF03349875","article-title":"Cyproheptadine treatment in Cushing's disease","volume":"19","author":"Tanakol","year":"1996","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"6","key":"10.1016\/j.nec.2012.06.012_bib51","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2265.1986.tb03621.x","article-title":"Response to neurotransmitter modulating drugs in patients with Cushing's disease","volume":"25","author":"Koppeschaar","year":"1986","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11102-005-1430-8","article-title":"PPAR-gamma in Cushing's disease","volume":"7","author":"Heaney","year":"2004","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib53","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/eje.0.1510173","article-title":"Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease","volume":"151","author":"Ambrosi","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib54","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2265.2006.02452.x","article-title":"Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease","volume":"64","author":"Pecori Giraldi","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"Suppl 1","key":"10.1016\/j.nec.2012.06.012_bib55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000314312","article-title":"Role of the PPAR-gamma system in normal and tumoral pituitary corticotropic cells and adrenal cells","volume":"92","author":"Mannelli","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib56","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1507\/endocrj1954.39.385","article-title":"Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease","volume":"39","author":"Mercado-Asis","year":"1992","journal-title":"Endocrinol Jpn"},{"issue":"7989","key":"10.1016\/j.nec.2012.06.012_bib57","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(76)90656-5","article-title":"Bromocriptine in Nelson's syndrome and Cushing's disease","volume":"2","author":"Lamberts","year":"1976","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib58","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/edrv-13-2-220","article-title":"Dopamine agonists and pituitary tumor shrinkage","volume":"13","author":"Bevan","year":"1992","journal-title":"Endocr Rev"},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2265.1990.tb00855.x","article-title":"The effect of cyproheptadine and\/or bromocriptine on plasma ACTH levels in patients cured of Cushing's disease by bilateral adrenalectomy","volume":"32","author":"Whitehead","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.nec.2012.06.012_bib60","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000082235","article-title":"Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment","volume":"62","author":"Casulari","year":"2004","journal-title":"Horm Res"},{"key":"10.1016\/j.nec.2012.06.012_bib61","unstructured":"Godbout A, Manavela M, Danilowicz K, et\u00a0al. Long-term therapy with cabergoline in Cushing's disease [abstract: P2\u2013130]. Presented at the Endocrine Society's 90th meeting. San Francisco, 2008."},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","article-title":"Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease","volume":"13","author":"Vilar","year":"2010","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.nec.2012.06.012_bib63","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.nec.2012.06.012_bib64","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000125200","article-title":"Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells","volume":"50","author":"Lamberts","year":"1989","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib65","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/eje.0.1300125","article-title":"Octreotide exerts different effects in\u00a0vivo and in\u00a0vitro in Cushing's disease","volume":"130","author":"Stalla","year":"1994","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib66","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1152\/ajpendo.00004.2005","article-title":"Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells","volume":"289","author":"van der Hoek","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.nec.2012.06.012_bib67","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2006-1245","article-title":"The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas","volume":"91","author":"Batista","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.nec.2012.06.012_bib68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","article-title":"Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial","volume":"94","author":"Boscaro","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.nec.2012.06.012_bib69","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1210\/jc.2009-2272","article-title":"Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial","volume":"95","author":"Petersenn","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.nec.2012.06.012_bib70","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1210\/jc.2003-031319","article-title":"The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion","volume":"89","author":"Murray","year":"2004","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.nec.2012.06.012_bib71","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1210\/jc.2009-1311","article-title":"Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy","volume":"94","author":"Ben-Shlomo","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"25","key":"10.1016\/j.nec.2012.06.012_bib72","doi-asserted-by":"crossref","first-page":"24011","DOI":"10.1074\/jbc.M501998200","article-title":"Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion","volume":"280","author":"Ben-Shlomo","year":"2005","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.nec.2012.06.012_bib73","unstructured":"The European Medicines Agency. Signifor. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002052\/smops\/Positive\/human_smop_000326.jsp&mid=WC0b01ac058001d127&jsenabled=true. Accessed January 23, 2012."},{"issue":"3","key":"10.1016\/j.nec.2012.06.012_bib74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/35106036","article-title":"The promise of retinoids to fight against cancer","volume":"1","author":"Altucci","year":"2001","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib75","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11154-008-9080-6","article-title":"Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas","volume":"10","author":"Labeur","year":"2009","journal-title":"Rev Endocr Metab Disord"},{"issue":"8","key":"10.1016\/j.nec.2012.06.012_bib76","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1172\/JCI11098","article-title":"Retinoic acid prevents experimental Cushing syndrome","volume":"108","author":"Paez-Pereda","year":"2001","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1016\/j.nec.2012.06.012_bib77","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1210\/me.2004-0471","article-title":"Alpha1-adrenergic receptor antagonists: novel therapy for pituitary adenomas","volume":"19","author":"Fernando","year":"2005","journal-title":"Mol Endocrinol"},{"issue":"12","key":"10.1016\/j.nec.2012.06.012_bib78","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1172\/JCI60417","article-title":"EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas","volume":"121","author":"Fukuoka","year":"2011","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.nec.2012.06.012_bib79","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1210\/jc.2011-0536","article-title":"Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome","volume":"96","author":"Kamenicky","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib80","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2265.1991.tb03547.x","article-title":"Ketoconazole treatment in Cushing's syndrome: experience in 34 patients","volume":"35","author":"Sonino","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"10.1016\/j.nec.2012.06.012_bib81","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1532-5415.1998.tb02723.x","article-title":"Corticotropin-dependent Cushing's syndrome in older people: presentation of five cases and therapeutical use of ketoconazole","volume":"46","author":"Berwaerts","year":"1998","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib82","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1507\/endocrj.47.401","article-title":"Long-term effects of ketoconazole in the treatment of residual or recurrent Cushing's disease","volume":"47","author":"Chou","year":"2000","journal-title":"Endocr J"},{"issue":"6","key":"10.1016\/j.nec.2012.06.012_bib83","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1210\/jcem-63-6-1365","article-title":"Use of ketoconazole in the treatment of Cushing's syndrome","volume":"63","author":"Loli","year":"1986","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.nec.2012.06.012_bib84","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2265.1987.tb01189.x","article-title":"Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome","volume":"27","author":"McCance","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"Suppl 3","key":"10.1016\/j.nec.2012.06.012_bib85","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000023539","article-title":"New medical approaches in pituitary adenomas","volume":"53","author":"Colao","year":"2000","journal-title":"Horm Res"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib86","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1210\/jcem-61-4-718","article-title":"Prolonged treatment of Cushing's disease by ketoconazole","volume":"61","author":"Sonino","year":"1985","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.nec.2012.06.012_bib87","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2265.1991.tb01737.x","article-title":"Use of ketoconazole in the treatment of Cushing's disease and ectopic ACTH syndrome","volume":"34","author":"Tabarin","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib88","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2265.1987.tb01174.x","article-title":"Response of pituitary-adrenal axis to corticotrophin releasing hormone in patients with Cushing's disease before and after ketoconazole treatment","volume":"27","author":"Boscaro","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib89","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1210\/edrv-7-4-409","article-title":"Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis","volume":"7","author":"Feldman","year":"1986","journal-title":"Endocr Rev"},{"key":"10.1016\/j.nec.2012.06.012_bib90","unstructured":"AHFS Consumer Medication Information. Ketoconazole. Available at: http:\/\/www.mhra.gov.uk\/Publications\/Safetyguidance\/DrugSafetyUpdate\/CON028267. Accessed January 23, 2012."},{"issue":"5","key":"10.1016\/j.nec.2012.06.012_bib91","doi-asserted-by":"crossref","first-page":"613","DOI":"10.7326\/0003-4819-92-5-613","article-title":"Sustained remission of Cushing's disease with mitotane and pituitary irradiation","volume":"92","author":"Schteingart","year":"1980","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.nec.2012.06.012_bib92","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM197903013000903","article-title":"Treatment of Cushing's disease by O, p'DDD. Survey of 62 cases","volume":"300","author":"Luton","year":"1979","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.nec.2012.06.012_bib93","first-page":"49","article-title":"The protracted effect of o, p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo","volume":"50","author":"Leiba","year":"1989","journal-title":"Ann Endocrinol (Paris)"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib94","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1517\/14728210903413522","article-title":"Drugs in the medical treatment of Cushing's syndrome","volume":"14","author":"Schteingart","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib95","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","article-title":"Short and long-term responses to metyrapone in the medical\u00a0management of 91 patients with Cushing's\u00a0syndrome","volume":"35","author":"Verhelst","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.nec.2012.06.012_bib96","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1530\/EJE-09-0923","article-title":"Pregnancy and pituitary disorders","volume":"162","author":"Karaca","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"4\u20136","key":"10.1016\/j.nec.2012.06.012_bib97","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0960-0760(94)90267-4","article-title":"Therapy of Cushing's\u00a0syndrome with steroid biosynthesis inhibitors","volume":"49","author":"Engelhardt","year":"1994","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"issue":"2","key":"10.1016\/j.nec.2012.06.012_bib98","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11102-011-0314-3","article-title":"Medical suppression of hypercortisolemia in Cushing's syndrome with particular consideration of etomidate","volume":"15","author":"Heyn","year":"2012","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.nec.2012.06.012_bib99","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1210\/jcem-70-5-1426","article-title":"Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects","volume":"70","author":"Schulte","year":"1990","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib100","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/00000542-200310000-00022","article-title":"Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate","volume":"99","author":"Paris","year":"2003","journal-title":"Anesthesiology"},{"issue":"9","key":"10.1016\/j.nec.2012.06.012_bib101","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1055\/s-2001-11477","volume":"126","author":"Herrmann","year":"2001","journal-title":"Dtsch Med Wochenschr"},{"issue":"3","key":"10.1016\/j.nec.2012.06.012_bib102","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1097\/PCC.0b013e318198b096","article-title":"A\u00a0novel use of etomidate for intentional adrenal suppression to control severe hypercortisolemia in childhood","volume":"10","author":"Mettauer","year":"2009","journal-title":"Pediatr Crit Care Med"},{"issue":"8","key":"10.1016\/j.nec.2012.06.012_bib103","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF01735795","article-title":"Nonhypnotic low-dose etomidate for rapid correction of hypercortisolaemia in Cushing's syndrome","volume":"66","author":"Allolio","year":"1988","journal-title":"Klin Wochenschr"},{"issue":"1","key":"10.1016\/j.nec.2012.06.012_bib104","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1213\/ane.0b013e318187ed37","article-title":"Etomidate infusion in the critical care setting for suppressing the acute phase of Cushing's syndrome","volume":"108","author":"Dabbagh","year":"2009","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1016\/j.nec.2012.06.012_bib105","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2265.1993.tb02391.x","article-title":"The relationship between cortisol production rate and serial serum cortisol estimation in patients on medical therapy for Cushing's syndrome","volume":"39","author":"Trainer","year":"1993","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.nec.2012.06.012_bib106","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/EJE-07-0458","article-title":"Mifepristone (RU 486) in Cushing's syndrome","volume":"157","author":"Johanssen","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.nec.2012.06.012_bib107","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1530\/EJE-09-0098","article-title":"Merits and pitfalls of mifepristone in Cushing's syndrome","volume":"160","author":"Castinetti","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.nec.2012.06.012_bib108","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1210\/jc.86.8.3568","article-title":"Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486)","volume":"86","author":"Chu","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.nec.2012.06.012_bib109","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/jcem-61-3-536","article-title":"Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486","volume":"61","author":"Nieman","year":"1985","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.nec.2012.06.012_bib110","doi-asserted-by":"crossref","unstructured":"Fleseriu M, Biller B, Findling J, et\u00a0al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with refractory Cushing syndrome: results from the study of the efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing Syndrome (SEISMIC). Presented at ENDO 2011. Boston, June 4, 2011.","DOI":"10.1210\/endo-meetings.2011.PART1.OR10.OR09-5"},{"issue":"6","key":"10.1016\/j.nec.2012.06.012_bib111","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.nec.2012.06.012_bib112","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1210\/jc.81.8.2885","article-title":"Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism","volume":"81","author":"Vignati","year":"1996","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5463","key":"10.1016\/j.nec.2012.06.012_bib113","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.288.5463.154","article-title":"Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity","volume":"288","author":"Rocheville","year":"2000","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.nec.2012.06.012_bib114","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N\u00a0Engl J Med"}],"container-title":["Neurosurgery Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042368012000873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042368012000873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T10:57:37Z","timestamp":1562237857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1042368012000873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":114,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1042368012000873"],"URL":"https:\/\/doi.org\/10.1016\/j.nec.2012.06.012","relation":{},"ISSN":["1042-3680"],"issn-type":[{"value":"1042-3680","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}